Obermatt
See Similar Stocks →

Flags

Financial distress

Biote

NMQ:BTMD · US0906831039
PharmaceuticalsSmall

360

47
EV / EBIT56
Price / Owner Earnings34
Owner Earnings Yield79
Dividend Yield1
Price/Sales96
EV / Gross Profit67
Price/Book88
Return on Capital96
Cash Return on Capital98
EBIT Margin95
Gross Profitability100
Cash Conversion80
Accruals81
Owner Earnings Margin85
Sales growth36
Profit Growth13
Long-Term EPS Growth29
Owner Earnings Growth37
Reinvestment42
Price momentum16
Debt load1
Refinancing94
Debt Payback18
Liquidity66
Analyst ratings50
Opinion Changes50
Price Target Upside8
Market mood70
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Biote clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees245
Websitehaymakeracquisition.com
ISINUS0906831039
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
MHealthWomen's HealthNutraceuticalDigital WellnessEndocrinologyClinical TrialsHealth CaremHealthTherapeutics

Description

biote Corp. (‘Biote’) operates in practice-building business within the hormone optimization space. Similar to a franchise model, the company provides the necessary components to enable Biote-certified practitioners to establish, build, and successf…

Analysis

Quality compounder

biote Corp. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 5.1× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is tepid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
50
2026

All-time high

50

Jun 2026

All-time low

20

Mar 2026

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
—
—
—
Price/Earnings
84
—
—
—
Price/Book
88
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
98
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Biote with its peers
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Corcept Therapeutics
NAQ:CORT
20
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Oramed Pharmaceuticals
NAQ:ORMP
47
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Harmony Biosciences Holdings
NMQ:HRMY
94
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Verrica Pharmaceuticals
NAQ:VRCA
55
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →